Please login to the form below

Not currently logged in
Email:
Password:

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace
AstraZeneca, Marc Dunoyer

AstraZeneca (AZ) has announced that Marc Dunoyer will take over from Simon Lowth as the company's chief financial officer.

The decision ends a near four-month search for a replacement after Lowth announced in July his intention to leave the company for a similar role at natural gas firm BG Group.

Dunoyer only joined AZ in June this year as executive VP, global portfolio and product strategy, to support the company's global restructuring programme. He was previously head of the rare diseases business at big pharma rivals GlaxoSmithKline (GSK).

AZ's CEO Pascal Soriot said he was “delighted” with the appointment of Dunoyer.

“Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership,” said Soriot.

Dunoyer will begin his new role on November 1, reporting directly to Soriot.

AZ said his replacement as as executive VP, global portfolio and product strategy will be announced separately.

1st November 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics